Media & Research

Geoffrey Herkes, PhD, to present results at American Academy of Neurology meeting in April. Steve Bryson, PhD | March 20, 2023 Symbyx Neuro, Symb...

ExclusiveBy Noah Yim9:58 PM March 16, 2023 Sydney Adventist Hospital director of research Geoffrey Herkes An infrared-emitting helmet can reduce th...

SYMBYX, an Australian medtech company developing light therapies for intractable disease conditions, today announced the results of a Sydney Advent...

Light therapy and Peripheral Neuropathy    What is peripheral neuropathy?  Peripheral neuropathy occurs when there is direct damage to a nerve outs...

Pain affects up to 85% of people with Parkinson's disease. For some people with PD, the pain is so severe that it is actually the most disabling pa...

  DESCRIPTION OF THE EVENT: SYMBYX Biome devices are the only medically-approved laser devices in the world for a reduction in Parkinson’s symp...

When it comes to Parkinson's disease, if we are only talking about “low dopamine levels”, then we are missing a very important part of the conversa...

  SYMBYX  Q&A session on light therapy, lead by you!  Panellists: Lakshi Vasudevan, SYMBYX Customer Care  Dr Katie McRae (DC), SYMBYX C...

This past Saturday, SYMBYX was featured in The Express UK; Parkinson’s (PD) is the world’s fastest growing neurodegenerative disease and second ...